TREX WIND-DOWN, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2021-12-08: Form 8-K; Period of report 2021-12-08; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2021-11-22: Form 8-K; Period of report 2021-11-22; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2021-11-15: Form 8-K; Period of report 2021-11-15; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2021-11-04: Form 8-K; Period of report 2021-11-02; Description 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2021-12-08 | 8-K | 2021-12-08 | 7.01 Regulation FD Disclosure | 7.01 On December 8, 2021, Timber Pharmaceuticals, Inc. (the “Company”) posted presentation materials (the “Investor Presentation”) on the Investor Relations section of its website, which is located at https://www.timberpharma.com/events-and-presentation. | tm2134878d1_8k.htm |
| 2021-11-22 | 8-K | 2021-11-22 | 7.01 Regulation FD Disclosure | 7.01 Timber Pharmaceuticals, Inc. has prepared presentation materials (the “Investor Presentation”) that management intends to use with its conference call to be held at 10 A.M. (EST) on November 22, 2021. | tm2133597d1_8k.htm |
| 2021-11-15 | 8-K | 2021-11-15 | 2.02 Results of Operations and Financial Condition | 2.02 On November 15, 2021, Timber Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results and certain other information for the quarter ended September 30, 2021. | tmbr-20211115x8k.htm |
| 2021-11-04 | 8-K | 2021-11-02 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On November 2, 2021, the Company issued a press release announcing the proposed public offering of its securities. | tm2131854d1_8k.htm |
| 2021-10-07 | 8-K | 2021-10-07 | 8.01 Other Events | 8.01 On October 7, 2021, Timber Pharmaceuticals, Inc. (the “Company”) issued a press release announcing top-line data from its Phase 2b CONTROL study evaluating TMB-001, its investigational topical isotretinoin formulated using the Company’s patented IPEG™ delivery system, in patients with moderate to severe subtypes of congenital ichthyosis. | tmbr-20211007x8k.htm |
| 2021-09-29 | 8-K | 2021-09-27 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 27, 2021, Timber Pharmaceuticals, Inc. (the “Company”) and Joseph Lucchese, the Company’s Chief Financial Officer, entered into an offer letter pursuant to which Mr. Lucchese agreed to provide full time services to the Company, and the Company agreed to compensate him for his increased workload by: (i) increasing his base salary to $350,000 per year commencing as of October 1, 2021, and (ii) increasing his eligibility for a bonus to up to 40% of his base salary based on company and individual targets to be developed, subject to continued employment and remaining in good standing on each payment date. | tmbr-20210927x8k.htm |
| 2021-09-16 | 8-K | 2021-09-14 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 14, 2021, the Compensation Committee (the “Committee”) of the Board of Directors of Timber Pharmaceuticals, Inc. (the “Company”) approved grants of stock options to purchase shares of Company common stock to certain of its executive officers under the Company’s 2020 Omnibus Incentive Plan, as amended, all with an exercise price of $0.8925 per share. | tmbr-20210914x8k.htm |
| 2021-09-13 | 8-K | 2021-09-10 | 7.01 Regulation FD Disclosure | 7.01 Timber Pharmaceuticals, Inc. has prepared presentation materials (the “Investor Presentation”) that management intends to use with its presentation at the H.C. Wainwright 23rd Annual Global Investment Conference to be held on September 13, 2021. | tm2127389d1_8k.htm |
| 2021-08-24 | 8-K | 2021-08-24 | 8.01 Other Events | 8.01 On August 24, 2021, Timber Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the last-patient, last-visit milestone in its Phase 2b CONTROL study evaluating its lead asset, TMB-001, the Company’s topical pharmaceutical composition of isotretinoin, for the treatment of moderate to severe subtypes of congenital ichthyosis. | tmbr-20210824x8k.htm |
| 2021-08-10 | 8-K | 2021-08-10 | 2.02 Results of Operations and Financial Condition | 2.02 On August 10, 2021, Timber Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results and certain other information for the quarter ended June 30, 2021. | tmbr-20210810x8k.htm |
| 2021-07-02 | 8-K | 2021-07-01 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On July 1, 2021, Timber Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). | tm2121243-1_8k.htm |
| 2021-07-01 | 8-K | 2021-07-01 | 7.01 Regulation FD Disclosure | 7.01 On July 1, 2021, Timber Pharmaceuticals, Inc. posted presentation materials (the “Investor Presentation”) on the Investor Relations section of its website, which is located at https://www.timberpharma.com/events-and-presentation. | tm2120982d1_8k.htm |
| 2021-06-03 | 8-K | 2021-06-03 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On June 3, 2021, Timber Pharmaceuticals, Inc. (the “Company”) announced that the Company’s 2021 Annual Meeting of Stockholders (the “Annual Meeting”) was convened without a quorum. | tm2118480d1_8k.htm |
| 2021-05-26 | 8-K | 2021-05-26 | 8.01 Other Events | 8.01 On May 26, 2021, Timber Pharmaceuticals, Inc., a Delaware corporation (the “Company”), announced the completion of patient enrollment in its Phase 2b CONTROL Study evaluating its lead asset, TMB-001, the Company’s topical pharmaceutical composition of isotretinoin, for the treatment of moderate to severe subtypes of congenital ichthyosis. | tm2117637d1_8k.htm |
| 2021-05-11 | 8-K | 2021-05-11 | 2.02 Results of Operations and Financial Condition | 2.02 On May 11, 2021, Timber Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results and certain other information for the quarter ended March 31, 2021. | tm2115903d1_8k.htm |
| 2021-04-28 | 8-K | 2021-04-28 | 8.01 Other Events | 8.01 On April 28, 2021, Timber Pharmaceuticals, Inc., a Delaware corporation (the “Company”), announced that the Japanese Patent Office has decided to grant a patent (No. 2018-542677) for its lead asset, TMB-001, the Company’s topical pharmaceutical composition of isotretinoin that is currently being evaluated for the treatment of moderate to severe subtypes of congenital ichthyosis. | tm2114339d1_8k.htm |
| 2021-04-23 | 8-K | 2021-04-23 | 8.01 Other Events | 8.01 On April 23, 2021, Timber Pharmaceuticals, Inc., a Delaware corporation (the “Company”), announced that its Chief Executive Officer, John Koconis, has been appointed as Chairman of the Board of Directors (the “Board”). | tm2113798d1_8k.htm |
| 2021-04-16 | 8-K | 2021-04-13 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 13, 2021, Timber Pharmaceuticals, Inc. (the “Company”) received notice from Michael Derby, Executive Chairman of the Company’s Board of Directors (the “Board”), that he will step down and resign as an officer and director of the Company effective April 16, 2021. | tm2113216d1_8k.htm |
| 2021-03-23 | 8-K | 2021-03-23 | 2.02 Results of Operations and Financial Condition | 2.02 On March 23, 2021, Timber Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results and certain other information for the year ended December 31, 2020. | tm2110410d1_8k.htm |
| 2021-03-17 | 8-K | 2021-03-17 | 8.01 Other Events | 8.01 On March 17, 2021, Timber Pharmaceuticals, Inc., a Delaware corporation (the “Company”), announced that its development partner, AFT Pharmaceuticals Limited, a New Zealand company, number 873005, has entered into a licensing and development agreement for Pascomer® (TMB-002) in Europe with Desitin Arzneimittel GmbH. | tm2110027d1_8k.htm |
| 2021-03-16 | 8-K | 2021-03-10 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 The information under Item 1.01 above is incorporated by reference into this Item 2.03, and is qualified in its entirety by reference to the full text of the Lease Agreement, a copy of which is filed as Exhibit 10.1 to this Report on Form 8-K and is incorporated herein by reference. | tm219914d1_8k.htm |
| 2021-02-04 | 8-K | 2021-02-04 | 7.01 Regulation FD Disclosure | 7.01 On February 4, 2021, Timber Pharmaceuticals, Inc. (the “Company”) posted presentation materials (the “Investor Presentation”) on the Investor Relations section of its website, which is located at https://www.timberpharma.com/events-and-presentation. | tm215388d1_8k.htm |
| 2021-01-25 | 8-K | 2021-01-19 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 25, 2021, Timber Pharmaceuticals, Inc. (the “Company”) announced that Alan Mendelsohn, M.D., has been appointed as the Company’s Chief Medical Officer, effective February 4, 2021 (the “Effective Date”). | tm214031d1_8k.htm |
| 2021-01-13 | 8-K | 2021-01-12 | 8.01 Other Events | 8.01 On January 12, 2021, Timber Pharmaceuticals, Inc. (the “Company”) announced that the U.S. Food and Drug Administration has granted orphan drug designation to TMB-003, the Company’s locally delivered formulation of sitaxsentan, for the treatment of systemic sclerosis. | tm212962d1_8k.htm |